{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:41:40Z","timestamp":1793320900229,"version":"4.5.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100012187","name":"St. Vincent's Clinic Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012187","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"Department of Health | National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Diabetes Australia Research Program, University of New South Wales Cardiac Vascular and Metabolic Medicine Theme, Jonathon and Melissa Green"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Insulin resistance is an underrecognized cardiovascular risk factor in type 1 diabetes. The effect of metformin on insulin resistance in adults with type 1 diabetes is unknown. Forty adults with type 1 diabetes, and twenty adults without diabetes were studied in a baseline only cross-sectional study assessing insulin resistance using the two-step hyperinsulinemic-euglycemic clamp. Participants with type 1 diabetes exhibited hepatic (EGP 64% higher), muscle (glucose infusion rate [GIR] 29% lower) and adipose (higher non-esterified fatty acids [NEFA]) insulin resistance. We then conducted a parallel group randomized, placebo-controlled trial to assess the efficacy of metformin 1500\u2009mg (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200920) versus placebo (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200920) in reducing insulin resistance in adults with type 1 diabetes over 26 weeks. The primary outcome was change in endogenous glucose production (EGP) during the low-dose phase of the clamp. Thirty seven of 40 adults with type 1 diabetes completed the study. At 26 weeks, there was no difference in change in EGP between metformin and placebo groups (mean difference 0.2 \u00b5mol\/kg fat-free mass [FFM]\/min [95%CI, \u22120.4 to 0.8 \u00b5mol\/kgFFM\/min];\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.53). There was no increase in hypoglycemia or episodes of ketoacidosis in either group. These results do not support prescribing metformin to reduce hepatic insulin resistance in adults with type 1 diabetes. Australian New Zealand Clinical Trials Registry identifier, ACTRN12619001440112.\n                  <\/jats:p>","DOI":"10.1038\/s41467-025-65951-1","type":"journal-article","created":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T10:02:26Z","timestamp":1763978546000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Effect of metformin on insulin resistance in adults with type 1 diabetes: a 26-week randomized double-blind clinical trial"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8559-8387","authenticated-orcid":false,"given":"Jennifer R.","family":"Snaith","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7990-3197","authenticated-orcid":false,"given":"Nick","family":"Olsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1599-017X","authenticated-orcid":false,"given":"Greg M.","family":"Kowalski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0515-3343","authenticated-orcid":false,"given":"Clinton R.","family":"Bruce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9422-7852","authenticated-orcid":false,"given":"Dorit","family":"Samocha-Bonet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9021-9879","authenticated-orcid":false,"given":"Samuel N.","family":"Breit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3640-1370","authenticated-orcid":false,"given":"Deborah J.","family":"Holmes-Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry R.","family":"Greenfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,24]]},"reference":[{"key":"65951_CR1","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1056\/NEJMoa1608664","volume":"376","author":"A Rawshani","year":"2017","unstructured":"Rawshani, A. et al. Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes. N. Engl. J. Med. 376, 1407\u20131418 (2017).","journal-title":"N. Engl. J. Med."},{"key":"65951_CR2","doi-asserted-by":"publisher","first-page":"837","DOI":"10.2337\/dbi19-0026","volume":"69","author":"JM Gregory","year":"2020","unstructured":"Gregory, J. M., Cherrington, A. D. & Moore, D. J. The Peripheral Peril: Injected Insulin Induces Insulin Insensitivity in Type 1 Diabetes. Diabetes 69, 837\u2013847 (2020).","journal-title":"Diabetes"},{"key":"65951_CR3","doi-asserted-by":"publisher","first-page":"306","DOI":"10.2337\/db10-0328","volume":"60","author":"IE Schauer","year":"2011","unstructured":"Schauer, I. E. et al. Insulin Resistance, Defective Insulin-Mediated Fatty Acid Suppression, and Coronary Artery Calcification in Subjects With and Without Type 1 Diabetes. Diabetes 60, 306\u2013314 (2011).","journal-title":"Diabetes"},{"key":"65951_CR4","doi-asserted-by":"crossref","unstructured":"Sun, R. et al. Association of Insulin Resistance With Cardiovascular Disease and All-Cause Mortality in Type 1 Diabetes: Systematic Review and Meta-analysis. Diabetes Care 47, 2266\u20132274 (2024).","DOI":"10.2337\/dc24-0475"},{"key":"65951_CR5","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1210\/jc.2011-3172","volume":"97","author":"BC Bergman","year":"2012","unstructured":"Bergman, B. C. et al. Features of Hepatic and Skeletal Muscle Insulin Resistance Unique to Type 1 Diabetes. J. Clin. Endocrinol. Metab. 97, 1663\u20131672 (2012).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"65951_CR6","doi-asserted-by":"publisher","first-page":"3647","DOI":"10.1210\/jc.2018-00433","volume":"103","author":"M Cree-Green","year":"2018","unstructured":"Cree-Green, M. et al. Youth With Type 1 Diabetes Have Adipose, Hepatic, and Peripheral Insulin Resistance.  J. Clin. Endocrinol. Metab. 103, 3647\u20133657 (2018).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"65951_CR7","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1210\/jc.2009-1756","volume":"95","author":"KJ Nadeau","year":"2010","unstructured":"Nadeau, K. J. et al. Insulin Resistance in Adolescents with Type 1 Diabetes and Its Relationship to Cardiovascular Function.  J. Clin. Endocrinol. Metab. 95, 513\u2013521 (2010).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"65951_CR8","doi-asserted-by":"publisher","first-page":"2390","DOI":"10.1056\/NEJMe1711296","volume":"377","author":"DM Nathan","year":"2017","unstructured":"Nathan, D. M. Adjunctive Treatments for Type 1 Diabetes. N. Engl. J. Med. 377, 2390\u20132391 (2017).","journal-title":"N. Engl. J. Med."},{"key":"65951_CR9","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.tem.2019.11.007","volume":"31","author":"JR Snaith","year":"2020","unstructured":"Snaith, J. R., Holmes-Walker, D. J. & Greenfield, J. R. Reducing Type 1 Diabetes Mortality: Role for Adjunctive Therapies? Trends Endocrinol. Metab. 31, 150\u2013164 (2020).","journal-title":"Trends Endocrinol. Metab."},{"key":"65951_CR10","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1210\/endrev\/bnaa023","volume":"42","author":"TE LaMoia","year":"2021","unstructured":"LaMoia, T. E. & Shulman, G. I. Cellular and Molecular Mechanisms of Metformin Action. Endocr. Rev. 42, 77\u201396 (2021).","journal-title":"Endocr. Rev."},{"key":"65951_CR11","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1038\/s41586-019-1911-y","volume":"578","author":"AP Coll","year":"2020","unstructured":"Coll, A. P. et al. GDF15 mediates the effects of metformin on body weight and energy balance. Nature 578, 444\u2013448 (2020).","journal-title":"Nature"},{"key":"65951_CR12","doi-asserted-by":"publisher","first-page":"426","DOI":"10.2337\/db23-0705","volume":"73","author":"SY Zhang","year":"2024","unstructured":"Zhang, S. Y., Danaei, Z., Bruce, K., Chiu, J. F. M. & Lam, T. K. T. Acute Activation of GFRAL in the Area Postrema Contributes to Glucose Regulation Independent of Weight. Diabetes 73, 426\u2013433 (2024).","journal-title":"Diabetes"},{"key":"65951_CR13","doi-asserted-by":"crossref","unstructured":"Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 352, 854\u2013865 (1998).","DOI":"10.1016\/S0140-6736(98)07037-8"},{"key":"65951_CR14","doi-asserted-by":"publisher","unstructured":"Liu, Y. et al. Vascular and metabolic effects of metformin added to insulin therapy in patients with type 1 diabetes: A systematic review and meta-analysis. Diabetes Metab. Res. Rev. 36, https:\/\/doi.org\/10.1002\/dmrr.3334 (2020).","DOI":"10.1002\/dmrr.3334"},{"key":"65951_CR15","doi-asserted-by":"publisher","first-page":"3265","DOI":"10.1210\/jc.2019-00129","volume":"104","author":"M Cree-Green","year":"2019","unstructured":"Cree-Green, M. et al. Metformin Improves Peripheral Insulin Sensitivity in Youth With Type 1 Diabetes.  J. Clin. Endocrinol. Metab. 104, 3265\u20133278 (2019).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"65951_CR16","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1161\/CIRCULATIONAHA.118.035525","volume":"138","author":"P Bjornstad","year":"2018","unstructured":"Bjornstad, P. et al. Metformin Improves Insulin Sensitivity and Vascular Health in Youth With Type 1 Diabetes Mellitus: Randomized Controlled Trial. Circulation 138, 2895\u20132907 (2018).","journal-title":"Circulation"},{"key":"65951_CR17","doi-asserted-by":"publisher","first-page":"4448","DOI":"10.1210\/jc.2017-00781","volume":"102","author":"JJA Anderson","year":"2017","unstructured":"Anderson, J. J. A. et al. Effect of Metformin on Vascular Function in Children With Type 1 Diabetes: A 12-Month Randomized Controlled Trial.  J. Clin. Endocrinol. Metab. 102, 4448\u20134456 (2017).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"65951_CR18","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1530\/eje.0.1490323","volume":"149","author":"S Sarnblad","year":"2003","unstructured":"Sarnblad, S., Kroon, M. & Aman, J. Metformin as additional therapy in adolescents with poorly controlled type 1 diabetes: randomised placebo-controlled trial with aspects on insulin sensitivity. Eur. J. Endocrinol. 149, 323\u2013329 (2003).","journal-title":"Eur. J. Endocrinol."},{"key":"65951_CR19","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1161\/01.CIR.0000105767.94169.E3","volume":"109","author":"T Weber","year":"2004","unstructured":"Weber, T. et al. Arterial stiffness, wave reflections, and the risk of coronary artery disease. Circulation 109, 184\u2013189 (2004).","journal-title":"Circulation"},{"key":"65951_CR20","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1007\/s11892-016-0751-5","volume":"16","author":"MM Kelsey","year":"2016","unstructured":"Kelsey, M. M. & Zeitler, P. S. Insulin Resistance of Puberty. Curr. Diab Rep. 16, 64 (2016).","journal-title":"Curr. Diab Rep."},{"key":"65951_CR21","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1007\/s00125-015-3844-9","volume":"59","author":"LJ McCreight","year":"2016","unstructured":"McCreight, L. J., Bailey, C. J. & Pearson, E. R. Metformin and the gastrointestinal tract. Diabetologia 59, 426\u2013435 (2016).","journal-title":"Diabetologia"},{"key":"65951_CR22","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s00259-007-0563-6","volume":"35","author":"E Gontier","year":"2008","unstructured":"Gontier, E. et al. High and typical 18F-FDG bowel uptake in patients treated with metformin. Eur. J. Nucl. Med. Mol. Imaging 35, 95\u201399 (2008).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"65951_CR23","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/s43856-025-00755-4","volume":"5","author":"K Sakaguchi","year":"2025","unstructured":"Sakaguchi, K. et al. Metformin-regulated glucose flux from the circulation to the intestinal lumen. Commun. Med. 5, 44 (2025).","journal-title":"Commun. Med."},{"key":"65951_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2023.106057","volume":"26","author":"L Zubiaga","year":"2023","unstructured":"Zubiaga, L. et al. Oral metformin transiently lowers post-prandial glucose response by reducing the apical expression of sodium-glucose co-transporter 1 in enterocytes. iScience 26, 106057 (2023).","journal-title":"iScience"},{"key":"65951_CR25","doi-asserted-by":"publisher","first-page":"280","DOI":"10.2337\/dc16-1682","volume":"40","author":"HC Gerstein","year":"2017","unstructured":"Gerstein, H. C. et al. Growth Differentiation Factor 15 as a Novel Biomarker for Metformin. Dia Care 40, 280\u2013283 (2017).","journal-title":"Dia Care"},{"key":"65951_CR26","doi-asserted-by":"publisher","DOI":"10.1111\/ijpo.12845","volume":"17","author":"G Carreras-Badosa","year":"2022","unstructured":"Carreras-Badosa, G. et al. A 24-month metformin treatment study of children with obesity: Changes in circulating GDF -15 and associations with changes in body weight and visceral fat. Pediatr. Obes. 17, e12845 (2022).","journal-title":"Pediatr. Obes."},{"key":"65951_CR27","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1161\/01.RES.0000202805.73038.48","volume":"98","author":"T Kempf","year":"2006","unstructured":"Kempf, T. et al. The Transforming Growth Factor-\u03b2 Superfamily Member Growth-Differentiation Factor-15 Protects the Heart From Ischemia\/Reperfusion Injury. Circ. Res. 98, 351\u2013360 (2006).","journal-title":"Circ. Res."},{"key":"65951_CR28","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1016\/j.cell.2019.07.033","volume":"178","author":"HH Luan","year":"2019","unstructured":"Luan, H. H. et al. GDF15 Is an Inflammation-Induced Central Mediator of Tissue Tolerance. Cell 178, 1231\u20131244.e11 (2019).","journal-title":"Cell"},{"key":"65951_CR29","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.tem.2020.10.004","volume":"31","author":"L Rochette","year":"2020","unstructured":"Rochette, L., Zeller, M., Cottin, Y. & Vergely, C. Insights Into Mechanisms of GDF15 and Receptor GFRAL: Therapeutic Targets. Trends Endocrinol. Metab. 31, 939\u2013951 (2020).","journal-title":"Trends Endocrinol. Metab."},{"key":"65951_CR30","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1038\/nm.4392","volume":"23","author":"SE Mullican","year":"2017","unstructured":"Mullican, S. E. et al. GFRAL is the receptor for GDF15 and the ligand promotes weight loss in mice and nonhuman primates. Nat. Med. 23, 1150\u20131157 (2017).","journal-title":"Nat. Med."},{"key":"65951_CR31","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/ijo.2017.258","volume":"42","author":"VW Tsai","year":"2018","unstructured":"Tsai, V. W. et al. Treatment with the TGF-b superfamily cytokine MIC-1\/GDF15 reduces the adiposity and corrects the metabolic dysfunction of mice with diet-induced obesity. Int. J. Obes. 42, 561\u2013571 (2018).","journal-title":"Int. J. Obes."},{"key":"65951_CR32","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1007\/s00125-017-4342-z","volume":"60","author":"G Rena","year":"2017","unstructured":"Rena, G., Hardie, D. G. & Pearson, E. R. The mechanisms of action of metformin. Diabetologia 60, 1577\u20131585 (2017).","journal-title":"Diabetologia"},{"key":"65951_CR33","doi-asserted-by":"publisher","unstructured":"Gregory, J. M. et al. Iatrogenic Hyperinsulinemia, Not Hyperglycemia, Drives Insulin Resistance in Type 1 Diabetes as Revealed by Comparison to GCK-MODY (MODY2). Diabetes, https:\/\/doi.org\/10.2337\/db19-0324 (2019).","DOI":"10.2337\/db19-0324"},{"key":"65951_CR34","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1161\/hc0502.103333","volume":"105","author":"G Arcaro","year":"2002","unstructured":"Arcaro, G. et al. Insulin Causes Endothelial Dysfunction in Humans: Sites and Mechanisms. Circulation 105, 576\u2013582 (2002).","journal-title":"Circulation"},{"key":"65951_CR35","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/S2213-8587(21)00246-1","volume":"9","author":"B Van der Schueren","year":"2021","unstructured":"Van der Schueren, B. et al. Obesity in people living with type 1 diabetes.  Lancet Diab. Endocrinol. 9, 776\u2013785 (2021).","journal-title":"Lancet Diab. Endocrinol."},{"key":"65951_CR36","doi-asserted-by":"publisher","first-page":"657","DOI":"10.2337\/dc18-1574","volume":"42","author":"BH Braffett","year":"2019","unstructured":"Braffett, B. H. et al. Association of Insulin Dose, Cardiometabolic Risk Factors, and Cardiovascular Disease in Type 1 Diabetes During 30 Years of Follow-up in the DCCT\/EDIC Study. Diab. Care 42, 657\u2013664 (2019).","journal-title":"Diab. Care"},{"key":"65951_CR37","doi-asserted-by":"publisher","first-page":"h3234","DOI":"10.1136\/bmj.h3234","volume":"350","author":"I Steineck","year":"2015","unstructured":"Steineck, I. et al. Insulin pump therapy, multiple daily injections, and cardiovascular mortality in 18 168 people with type 1 diabetes: observational study. BMJ 350, h3234\u2013h3234 (2015).","journal-title":"BMJ"},{"key":"65951_CR38","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/S2213-8587(17)30194-8","volume":"5","author":"JR Petrie","year":"2017","unstructured":"Petrie, J. R. et al. Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial. Lancet Diab. Endocrinol. 5, 597\u2013609 (2017).","journal-title":"Lancet Diab. Endocrinol."},{"key":"65951_CR39","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1161\/CIRCULATIONAHA.120.046361","volume":"142","author":"P Willeit","year":"2020","unstructured":"Willeit, P. et al. Carotid Intima-Media Thickness Progression as Surrogate Marker for Cardiovascular Risk: Meta-Analysis of 119 Clinical Trials Involving 100 667 Patients. Circulation 142, 621\u2013642 (2020).","journal-title":"Circulation"},{"key":"65951_CR40","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1111\/dom.14350","volume":"23","author":"JG Timmons","year":"2021","unstructured":"Timmons, J. G. et al. Metformin and carotid intima-media thickness in never-smokers with type 1 diabetes: The REMOVAL trial. Diab. Obes. Metab. 23, 1371\u20131378 (2021).","journal-title":"Diab. Obes. Metab."},{"key":"65951_CR41","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1210\/er.2008-0024","volume":"29","author":"MA Cornier","year":"2008","unstructured":"Cornier, M. A. et al. The Metabolic Syndrome. Endocr. Rev. 29, 777\u2013822 (2008).","journal-title":"Endocr. Rev."},{"key":"65951_CR42","doi-asserted-by":"publisher","first-page":"4865","DOI":"10.2147\/DMSO.S343514","volume":"14","author":"K Guo","year":"2021","unstructured":"Guo, K., Tian, Q., Yang, L. & Zhou, Z. The Role of Glucagon in Glycemic Variability in Type 1 Diabetes: A Narrative Review. Diab. Metab. Syndr. Obes. 14, 4865\u20134873 (2021).","journal-title":"Diab. Metab. Syndr. Obes."},{"key":"65951_CR43","doi-asserted-by":"publisher","first-page":"e2778","DOI":"10.1210\/clinem\/dgaa259","volume":"105","author":"JCM Ng","year":"2020","unstructured":"Ng, J. C. M. & Schooling, C. M. Effect of Glucagon on Ischemic Heart Disease and Its Risk Factors: A Mendelian Randomization Study.  J. Clin. Endocrinol. Metab. 105, e2778\u2013e2788 (2020).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"65951_CR44","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1172\/JCI77812","volume":"126","author":"VT Samuel","year":"2016","unstructured":"Samuel, V. T. & Shulman, G. I. The pathogenesis of insulin resistance: integrating signaling pathways and substrate flux. J. Clin. Investig. 126, 12\u201322 (2016).","journal-title":"J. Clin. Investig."},{"key":"65951_CR45","doi-asserted-by":"publisher","first-page":"626","DOI":"10.2337\/diabetes.49.4.626","volume":"49","author":"KV Williams","year":"2000","unstructured":"Williams, K. V., Erbey, J. R., Becker, D., Arslanian, S. & Orchard, T. J. Can clinical factors estimate insulin resistance in type 1 diabetes? Diabetes 49, 626\u2013632 (2000).","journal-title":"Diabetes"},{"key":"65951_CR46","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1210\/jc.2014-3050","volume":"100","author":"G Llaurad\u00f3","year":"2015","unstructured":"Llaurad\u00f3, G. et al. Liver Fat Content and Hepatic Insulin Sensitivity in Overweight Patients With Type 1 Diabetes.  J. Clin. Endocrinol. Metab. 100, 607\u2013616 (2015).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"65951_CR47","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.2337\/dc13-2612","volume":"37","author":"J Sherr","year":"2014","unstructured":"Sherr, J. et al. Evolution of abnormal plasma glucagon responses to mixed-meal feedings in youth with type 1 diabetes during the first 2 years after diagnosis. Diab. Care 37, 1741\u20131744 (2014).","journal-title":"Diab. Care"},{"key":"65951_CR48","doi-asserted-by":"publisher","DOI":"10.1111\/dme.14564","volume":"38","author":"JR Snaith","year":"2021","unstructured":"Snaith, J. R. et al. Insulin resistance in type 1 diabetes managed with metformin (INTIMET): Study protocol of a double-blind placebo-controlled, randomised trial. Diabet. Med. 38, e14564 (2021).","journal-title":"Diabet. Med."},{"key":"65951_CR49","doi-asserted-by":"publisher","first-page":"734","DOI":"10.4236\/jbise.2011.411090","volume":"04","author":"M Saghaei","year":"2011","unstructured":"Saghaei, M. & Saghaei, S. Implementation of an open-source customizable minimization program for allocation of patients to parallel groups in clinical trials. J. Biomed. Sci. Eng. 04, 734\u2013739 (2011).","journal-title":"J. Biomed. Sci. Eng."},{"key":"65951_CR50","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1016\/S0161-6420(03)00475-5","volume":"110","author":"CP Wilkinson","year":"2003","unstructured":"Wilkinson, C. P. et al. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology 110, 1677\u20131682 (2003).","journal-title":"Ophthalmology"},{"key":"65951_CR51","first-page":"303","volume":"5","author":"D Du Bois","year":"1989","unstructured":"Du Bois, D. & Du Bois, E. F. A formula to estimate the approximate surface area if height and weight be known. 1916. Nutrition 5, 303\u2013311 (1989).","journal-title":"Nutrition"},{"key":"65951_CR52","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1111\/j.1365-2362.1992.tb01458.x","volume":"22","author":"JK Powrie","year":"1992","unstructured":"Powrie, J. K. et al. Incomplete suppression of hepatic glucose production in non-insulin dependent diabetes mellitus measured with [6,6 \u22122 H 2]glucose enriched glucose infusion during hyperinsulinaemic euglycaemic clamps. Eur. J. Clin. Invest. 22, 244\u2013253 (1992).","journal-title":"Eur. J. Clin. Invest."},{"key":"65951_CR53","doi-asserted-by":"publisher","first-page":"939","DOI":"10.2337\/db18-1138","volume":"68","author":"T Ang","year":"2019","unstructured":"Ang, T., Bruce, C. R. & Kowalski, G. M. Postprandial Aminogenic Insulin and Glucagon Secretion Can Stimulate Glucose Flux in Humans. Diabetes 68, 939\u2013946 (2019).","journal-title":"Diabetes"},{"key":"65951_CR54","doi-asserted-by":"publisher","first-page":"118","DOI":"10.2144\/02331rr03","volume":"33","author":"DA Brown","year":"2002","unstructured":"Brown, D. A. et al. Antibody-based approach to high-volume genotyping for MIC-1 polymorphism. Biotechniques 33, 118\u2013120 (2002). 122, 124 passim.","journal-title":"Biotechniques"},{"key":"65951_CR55","first-page":"4781","volume":"85","author":"AG Moore","year":"2000","unstructured":"Moore, A. G. et al. The Transforming Growth Factor-\u03b2 Superfamily Cytokine Macrophage Inhibitory Cytokine-1 Is Present in High Concentrations in the Serum of Pregnant Women1.  J. Clin. Endocrinol. Metab. 85, 4781\u20134788 (2000).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"65951_CR56","doi-asserted-by":"crossref","unstructured":"Twisk, J. et al. Different ways to estimate treatment effects in randomised controlled trials. Contemp. Clin. Trials Commun. 10, 80\u201385 (2018).","DOI":"10.1016\/j.conctc.2018.03.008"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-65951-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-65951-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-65951-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T10:02:31Z","timestamp":1763978551000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-65951-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,24]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["65951"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-65951-1","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,24]]},"assertion":[{"value":"15 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9884"}}